|
|
|
27.02.26 - 22:21
|
Prothena Announces up to $100 Million Share Repurchase Plan (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share.
Prothena had cash, cash equivalents and restricted cash of $308.4 million and no debt as of December 31, 2025. Excluding any potential purchases under this Share Repurchase Plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerativ...
|
|
|
|
|
27.02.26 - 21:45
|
Novo Nordisk Aktie: Eine Vergleichsstudie mit Sprengkraft (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär":
Alfred Maydorn vom Anlegermagazin "Der Aktionär" nimmt im Interview mit "Der Aktionär TV" die Aktie von Novo Nordisk A/S (ISIN: DK0062498333, WKN: A3EU6F, Ticker-Symbol: NOV, NASDAQ Kopenhagen-Symbol: NOVO B) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 14:24
|
Novo Nordisk Equal Weight (DPA-AFX)
|
|
|
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk mit einem Kursziel von 270 dänischen Kronen auf "Equal Weight" belassen. Der Start von Wegovy in Tablettenform laufe sehr stark weiter, selbst in dem ......
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 08:30
|
Cessatech A/S Announces Financial Results for the Full Year 2025 (Cision)
|
|
|
Copenhagen, Denmark - 27 February 2026 - Cessatech A/S (“Cessatech” or the “Company”), a late-stage paediatric specialty company developing and commercializing non-invasive hospital medicines for children, today announced financial results for the year ended December 31, 2025, which also includes financial results for the fourth quarter of 2025.
Full year 2025 for the period 1 January - 31 December (Q4'2025 results in brackets):
· Net revenue: KDKK 5,718 (1,989)
· Operating result: KDKK -14,967 (-1,836)
· Net result: KDKK -10,904 (-773)
· Cash at bank end of the period: KDKK 8,...
|
|
|
|
|
|
|
26.02.26 - 11:12
|
Novo Nordisk and Vivtex collaborate for oral medicines development (PBR)
|
|
|
Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered
The post Novo Nordisk and Vivtex collaborate for oral medicines development appeared first on Pharmaceutical Business review....
|
|
|
|
|
26.02.26 - 09:15
|
Novo Nordisk-Aktie: Kurssturz auf unter 30 Euro möglich (Sharedeals)
|
|
|
Die Aktie von Novo Nordisk galt lange als Inbegriff eines sicheren Wachstumsinvestments und als einer der größten Gewinner des globalen Pharma-Booms. Doch nach einer Serie enttäuschender Nachrichten und zunehmend kritischer Analystenstimmen beginnt sich das Bild zu drehen – und erstmals rücken auch deutlich tiefere Kursziele wieder in den Bereich des Möglichen. Der Börsenliebling verliert seinen […]
The post Novo Nordisk-Aktie: Kurssturz auf unter 30 Euro möglich first appeared on sharedeals.de....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
